<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2016-04-27">27 Apr 2016</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author role="corresp">
							<persName><forename type="first">Fergus</forename><forename type="middle">J</forename><surname>Couch</surname></persName>
							<email>couch.fergus@mayo.edu</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Policy-Epidemiology</orgName>
								<orgName type="department" key="dep2">186 Multidisciplinary Breast Center</orgName>
								<orgName type="department" key="dep3">Department of General Medical Oncology</orgName>
								<orgName type="institution">Stanford University School of Medicine</orgName>
								<address>
									<postCode>94305</postCode>
									<settlement>Stanford</settlement>
									<region>California</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="institution">University Hospitals</orgName>
								<address>
									<postCode>B-3000</postCode>
									<settlement>Leuven</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
							<affiliation key="aff2">
								<orgName type="department">Division of Cancer Epidemiology and Genetics</orgName>
								<orgName type="institution">National Cancer Institute</orgName>
								<address>
									<postCode>20892</postCode>
									<settlement>Bethesda</settlement>
									<region>Maryland</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff3">
								<orgName type="department">Servicio de Oncologı ´a Me ´dica</orgName>
								<orgName type="institution">Hospital Universitario La Paz</orgName>
								<address>
									<postCode>28046</postCode>
									<settlement>Madrid</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="department" key="dep1">Department of Biostatistics</orgName>
								<orgName type="department" key="dep2">190 Cancer Division</orgName>
								<orgName type="institution">Harvard School Of Public Health</orgName>
								<address>
									<postCode>02115</postCode>
									<settlement>Boston</settlement>
									<region>Massachusetts</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="institution">QIMR Berghofer Medical Research Institute</orgName>
								<address>
									<postCode>4029</postCode>
									<settlement>Brisbane</settlement>
									<region>Queensland</region>
									<country key="AU">Australia</country>
								</address>
							</affiliation>
							<affiliation key="aff6">
								<orgName type="department">Division of Cancer Epidemiology and Genetics</orgName>
								<orgName type="institution" key="instit1">National Cancer Institute</orgName>
								<orgName type="institution" key="instit2">National Institutes of Health</orgName>
								<address>
									<postCode>20850</postCode>
									<settlement>Rockville</settlement>
									<region>Maryland</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2016-04-27">27 Apr 2016</date>
						</imprint>
					</monogr>
					<idno type="MD5">9D25DA1A324B9E4001333FB4D3D29BAC</idno>
					<idno type="DOI">10.1038/ncomms11375</idno>
					<note type="submission">Received 16 Apr 2015 | Accepted 21 Mar 2016 |</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:14+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Common variants in 94 loci have been associated with breast cancer including 15 loci with genome-wide significant associations (Po5 Â 10 À 8 ) with oestrogen receptor (ER)-negative breast cancer and BRCA1-associated breast cancer risk.</s><s>In this study, to identify new ER-negative susceptibility loci, we performed a meta-analysis of 11 genome-wide association studies (GWAS) consisting of 4,939 ER-negative cases and 14,352 controls, combined with 7,333 ER-negative cases and 42,468 controls and 15,252 BRCA1 mutation carriers genotyped on the iCOGS array.</s><s>We identify four previously unidentified loci including two loci at 13q22 near KLF5, a 2p23.2</s><s>locus near WDR43 and a 2q33 locus near PPIL3 that display genome-wide significant associations with ER-negative breast cancer.</s><s>In addition, 19 known breast cancer risk loci have genome-wide significant associations and 40 had moderate associations (Po0.05) with ER-negative disease.</s><s>Using functional and eQTL studies we implicate TRMT61B and WDR43 at 2p23.2 and PPIL3 at 2q33 in ER-negative breast cancer aetiology.</s><s>All ER-negative loci combined account for B11% of familial relative risk for ER-negative disease and may contribute to improved ER-negative and BRCA1 breast cancer risk prediction.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>B</head><p><s>reast cancer is a heterogeneous disease that can be separated into clinical subtypes based on tumour histological markers, such as the oestrogen receptor (ER).</s><s>ER-negative disease accounts for 20-30% of all breast cancers, is more common in women diagnosed at young age and in women of African ancestry <ref type="bibr">1</ref> , and is associated with worse shortterm outcome than ER-positive disease.</s><s>ER-negative and ERpositive breast cancer also exhibit different patterns of genetic susceptibility <ref type="bibr" target="#b1">2</ref> .</s><s>Currently, 94 loci containing common breast cancer risk-associated variants have been associated with breast cancer through genome-wide association studies (GWAS), and large replication studies <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr">[5]</ref><ref type="bibr" target="#b5">[6]</ref><ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref><ref type="bibr">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref><ref type="bibr" target="#b13">[14]</ref><ref type="bibr" target="#b14">[15]</ref><ref type="bibr" target="#b15">[16]</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref> .</s><s>However, only 14 loci have shown genome-wide significant associations (Po5 Â 10 À 8 ) with ER-negative disease <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b16">[17]</ref><ref type="bibr" target="#b17">[18]</ref><ref type="bibr" target="#b18">[19]</ref><ref type="bibr" target="#b19">[20]</ref> .</s><s>While this partly reflects the smaller sample size for ER-negative disease, the majority of the known breast cancer loci show differences in relative risk by subtype.</s><s>In particular, 6 of the 14 loci associated with ER-negative disease at genome-wide significance show no evidence of association with ER-positive disease <ref type="bibr" target="#b19">20</ref> .</s><s>The alleles associated with ER-negative breast cancer <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b16">17</ref> at these loci have also been associated with breast cancer risk in BRCA1 mutation carriers <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b21">22</ref> , consistent with the finding that the majority of breast tumours arising in BRCA1 mutation carriers show low/absent expression of ER <ref type="bibr" target="#b22">[23]</ref><ref type="bibr" target="#b23">[24]</ref><ref type="bibr" target="#b24">[25]</ref> .</s><s>These observations suggest that a meta-analysis of results from ER-negative breast cancer and BRCA1 breast cancer association studies could identify additional ER-negative susceptibility loci that were not found previously because of limited sample size.</s></p><p><s>In this study, we carried out a meta-analysis of breast cancer GWAS studies and found four new loci associated with developing ER-negative breast cancer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head><p><s>Associations with ER-negative breast cancer.</s><s>Genotype data for this meta-analysis were obtained from three sources: (1) 11 breast cancer GWAS included 5,139 ER-negative breast cancer cases and 14,352 controls (Supplementary Table <ref type="table" target="#tab_0">1</ref>); (2) The Breast Cancer Association Consortium (BCAC) included 7,333 ER-negative breast cancer cases and 42,468 study-matched controls genotyped on the iCOGS (Collaborative Oncological Gene-environment Study) custom array 3 ; (3) The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) <ref type="bibr" target="#b25">26</ref> included 15,252 BRCA1 mutation carriers (7,797 with breast cancer and 7,455 unaffected) genotyped on the iCOGS array (Supplementary Tables <ref type="table" target="#tab_1">2-4</ref>).</s><s>Imputation was performed using the 1000 Genomes project as a reference <ref type="bibr" target="#b19">20,</ref><ref type="bibr" target="#b27">27</ref> , and a meta-analysis was performed based on 10,909,381 common single-nucleotide polymorphisms (SNPs) that passed quality control (Supplementary Table <ref type="table" target="#tab_0">1</ref>).</s></p><p><s>We first considered SNPs in 94 regions in which genome-wide significant associations for breast cancer had been identified (Methods) <ref type="bibr" target="#b19">20</ref> .</s><s>In 55 of these, the SNP most significantly associated with overall breast cancer risk was significantly associated (Po0.05) with ER-negative breast cancer in the meta-analysis.</s><s>Four more were associated with ER-negative breast cancer in the general population (Po0.05) but not in the meta-analysis, and 15 displayed genome-wide significant (Po5 Â 10 À 8 ) associations with ER-negative breast cancer (Supplementary Table <ref type="table">5</ref>).</s><s>In addition, new SNPs in three loci (rs10864459 from 1p36.2 PEX14, rs11903787 from INHBB and rs4980383 from 11p15.5 LSP1) were found to have genome-wide significant associations with ER-negative disease (Table <ref type="table" target="#tab_0">1</ref>, Fig. <ref type="figure" target="#fig_0">1</ref>, Supplementary Table <ref type="table">5</ref>).</s><s>Likewise, SNPs in the TCF7L2 locus previously associated with BRCA1 breast cancer <ref type="bibr" target="#b21">22</ref> and ER-positive breast cancer <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b19">20</ref> showed genome-wide significant associations with ER-negative breast cancer (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Interestingly multiple independent signals in several loci were associated with ER-negative breast cancer.</s><s>In particular, three independent regions in the TERT locus <ref type="bibr" target="#b28">28</ref> , two regions in PTHLH, and two regions in ESR1 displayed genomewide significant associations with ER-negative breast cancer (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Furthermore, while previous studies established genome-wide significant associations with ER-negative disease for rs11075995 in one 16q12.2</s><s>FTO locus 17 , rs17817449 (r 2 ¼ 0.035) from a second FTO locus located 40 kb proximal to the rs11075995 tagged locus 17 also displayed near-genome-wide significance (P ¼ 5.26 Â 10 À 8 ) with ER-negative breast cancer in the meta-analysis (Table <ref type="table" target="#tab_0">1</ref>).</s><s>In addition to the breast cancer loci established in studies of European women, three additional breast cancer risk loci were recently identified in GWAS of Asian women.</s><s>To generalize the results to other populations, associations between the three SNPs and breast cancer in the European, African American and Asian populations in the iCOGS study were evaluated.</s><s>SNP rs2290203 showed only weak evidence of association (P ¼ 0.02), and rs4951011 and rs10474352 SNPs showed no evidence of association with ER-negative breast cancer in the white European meta-analysis (Supplementary Table <ref type="table">6</ref>).</s></p><p><s>Among the 94 known risk loci from white European and three from Asian populations, only 24 contained SNPs with some evidence of association (Po0.05) with breast cancer risk among BRCA1 mutation carriers alone.</s><s>These included 21 loci based on known index SNPs (Supplementary Table <ref type="table">5</ref>) along with new SNPs from the meta-analysis in the PEX14 (rs10864459), INHBB (rs11903787) and PTHLH (rs7297051) loci (Table <ref type="table" target="#tab_0">1</ref>).</s><s>Only the ESR1 (rs2046210), TERT (rs2242652) and two 19p13.1 (rs8170; rs56069439) loci had genome-wide significant associations with breast cancer risk for BRCA1 mutation carriers alone (Table <ref type="table" target="#tab_0">1</ref>, Supplementary Table <ref type="table">5</ref>).</s><s>However, 15 of the 19 risk loci that reached genome-wide significance for ER-negative disease in the meta-analysis showed some evidence of association (Po0.05) with breast cancer risk for BRCA1 mutation carriers using a retrospective likelihood analysis <ref type="bibr" target="#b11">12</ref> .</s><s>These SNPs had hazard ratio (HR) estimates in BRCA1 carriers that were similar to the odds ratio (OR) estimates for ER-negative breast cancer (Table <ref type="table" target="#tab_0">1</ref>).</s><s>In contrast, four SNPs in the LGR6, 2p24.1,</s><s>ZNF365 and FTO loci had HR estimates ranging from 0.97 to 1.01 and were not significantly associated (P40.05) with breast cancer risk for BRCA1 mutation carriers.</s><s>No significant interactions between the known risk SNPs were observed when pairwise interactions were evaluated separately in the general population (BCAC-iCOGS) or in BRCA1 carriers after adjusting for multiple testing.</s></p><p><s>Genome-wide associations with ER-negative breast cancer.</s></p><p><s>Novel genome-wide significant associations (Po5 Â 10 À 8 ) were detected with imputed and genotyped SNPs on chromosomes 2p23.2 and 13q22 (Table <ref type="table" target="#tab_1">2</ref>, Fig. <ref type="figure" target="#fig_1">2</ref>, Supplementary Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>At 2p23.2, 79 SNPs exhibited genome-wide significant associations with ERnegative breast cancer (Fig. <ref type="figure" target="#fig_1">2</ref>, Supplementary Fig. <ref type="figure" target="#fig_1">2</ref>, Supplementary Table <ref type="table">7</ref>).</s><s>The most significant genotyped and imputed SNPs at these two loci were rs4577244 (P ¼ 1.0 Â 10 À 8 ) and rs67073037 (P ¼ 4.76 Â 10 À 9 ), respectively (Table <ref type="table" target="#tab_1">2</ref>).</s><s>To investigate the presence of independent signals at the 2p23.2</s><s>locus, conditional analyses were conducted adjusting for the lead SNP.</s><s>However, no significant (Po0.05)</s><s>associations were observed at 2p23.2 after adjusting for rs67073037.</s><s>In the 13q22 locus, rs6562760 was the most strongly associated (P ¼ 5.0 Â 10 À 10 ) SNP among 12 genome-wide significant SNPs (Table <ref type="table" target="#tab_1">2</ref>, Supplementary Table <ref type="table">8</ref>, Fig. <ref type="figure" target="#fig_1">2</ref>, Supplementary Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>Conditional analysis adjusting for rs6562760 yielded several SNPs with residual associations for ER-negative breast cancer, with rs17181761 (r 2 ¼ 0.51) as the most significantly associated (P ¼ 6.0 Â 10 À 6 ) (Supplementary Table <ref type="table">9</ref>).</s><s>No associations at Po10 À 4 remained after conditioning on both rs6562760 and rs17181761.</s><s>Thus, 13q22 appears to contain two independent ER-negative risk loci.</s><s>When considering only the data from the general population using the BCAC-iCOGS studies, no association between rs67073037 at 2p23.2 and ER-positive breast cancer was observed (Supplementary Table <ref type="table" target="#tab_0">10</ref>).</s><s>Consistent with this observation, a significant difference (P diff ¼ 4.45 Â 10 À 6 ) in the per-allele ORs for ER-positive and ER-negative breast cancer was detected.</s><s>In contrast, rs17181761 at 13q22 was weakly associated with ER-positive breast cancer (OR ¼ 1.03; P ¼ 0.030), but more strongly associated with ER-negative breast cancer (OR ¼ 1.08; P diff ¼ 5.82 Â 10 À 3 ; Supplementary Table <ref type="table" target="#tab_0">10</ref>).</s><s>Likewise, rs6562760 at 13q22 was more strongly associated with ERnegative than ER-positive breast cancer (ER-positive OR ¼ 0.98 versus ER-negative OR ¼ 0.92; P diff ¼ 0.028) (Supplementary Table <ref type="table" target="#tab_0">10</ref>).</s><s>Among ER-negative cases, no significant differences in the ORs for triple negative (ER-negative, progesterone receptor negative, HER2 negative) and non-triple-negative cases was observed (rs67073037, P diff ¼ 0.26; rs6562760, P diff ¼ 0.36; rs17181761, P diff ¼ 0.69).</s><s>Q-tests were used to assess heterogeneity.</s><s>These results suggest that the three risk loci are largely specific to ER-negative but not triple-negative breast cancer, in contrast to loci in the MDM4, LGR6, 19p13.1 and TERT regions <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b16">17</ref> .</s><s>To also investigate the impact of bilateral disease on the associations with ER-negative breast cancer in the general population, analyses were performed separately for BBCS alone, which oversampled for bilateral cases, and after exclusion of BBCS.</s><s>The risk estimates for each SNP (both in iCOGS and in the meta-analysis), after excluding BBCS, did not differ from the main results (Supplementary Table <ref type="table" target="#tab_0">11</ref>), and do not appear to be substantially influenced by bilateral cases.</s></p><p><s>Using the retrospective likelihood approach, index SNPs in the three 2p23.2</s><s>and 13q22 loci were all associated with BRCA1 breast cancer (rs67073037, P ¼ 4.58 Â 10 À 4 ; rs6562760, P ¼ 2.85 Â 10 À 6 ; rs17181761, P ¼ 9.29 Â 10 À 3 ; Table <ref type="table" target="#tab_1">2</ref>).</s><s>There were no significant differences in the associations with ER-positive and ER-negative disease among BRCA1 carriers (Supplementary Table <ref type="table" target="#tab_1">12</ref>).</s><s>A competing risks analysis in BRCA1 mutation carriers that accounted for simultaneous associations with breast and ovarian cancer risks found similar HR estimates for breast cancer and no evidence of association with ovarian cancer risk (Supplementary Table <ref type="table" target="#tab_0">13</ref>).</s><s>None of the SNPs were associated with overall breast cancer risk for BRCA2 mutation carriers (Supplementary Table <ref type="table" target="#tab_0">10</ref>).</s><s>There was also no significant evidence of heterogeneity (Po0.05) between the effect estimates for BRCA1 mutation carriers and ER-negative breast cancer in the general population (BCAC-iCOGS; Intraclass Correlation) <ref type="bibr" target="#b27">27</ref> .</s><s>Finally, no significant interactions between the three index SNPs and any of the 94 previously known loci were observed in BRCA1 carriers or in the general population after adjusting for multiple testing (Supplementary Table <ref type="table" target="#tab_0">14</ref>).</s></p><p><s>Association with ER-negative breast cancer in the 2q33 locus.</s><s>Analysis of genotyped and imputed SNPs around known risk loci also detected near-genome-wide significant associations with ER-negative breast cancer in a region on 2q33 containing several genes including PPIL3 and the known CASP8 risk locus (Table <ref type="table" target="#tab_1">2</ref>).</s><s>rs115635831 (P ¼ 1.26 Â 10 À 7 ) and rs188686860 (P ¼ 8.34 Â 10 À 8 ; r 2 ¼ 1.0), were the genotyped and imputed SNPs, respectively, most significantly associated with ER-negative breast cancer in this region.</s><s>These SNPs, along with the most proximal rs74943274 SNP (r 2 ¼ 0.97 with rs115635831), are located in CLK1 (Cdc-like kinase-1) and PPIL3 (Peptidylproplyl isomerase-Like 3) and are 350 kb upstream of CASP8 (Table <ref type="table" target="#tab_1">2</ref>, Fig. <ref type="figure" target="#fig_1">2</ref>).</s><s>All 157 SNPs with highly significant associations (Po1 Â 10 À 6 ) in this region, were in high linkage disequilibrium with rs188686860 and rs115635831 (r 2 40.90), and were located proximal (Hg19: 201,717,014-201,995,860) to the CASP8 gene (Supplementary Table <ref type="table" target="#tab_0">15</ref>).</s><s>Fine mapping of the CASP8 locus has recently identified four independent signals associated with overall breast cancer risk <ref type="bibr" target="#b29">29</ref> .</s><s>The index SNPs for these independent signals range across a 350-kb region from 202,036,478 to 202,379,828.</s><s>To determine whether these CASP8-associated signals accounted for the ER-negative associations in the meta-analysis, conditional analyses were conducted using the BCAC-iCOGS data.</s><s>After accounting for the four CASP8 signals, rs74943274 retained evidence of an association with overall breast cancer (P ¼ 1.44 Â 10 À 3 ) and a strong association with ER-negative breast cancer (P ¼ 1.34 Â 10 À 5 ; Supplementary Table <ref type="table" target="#tab_0">16</ref>; Supplementary Fig. <ref type="figure" target="#fig_1">2</ref>), suggesting that rs74943274 and rs115635831 represents a novel locus associated with ER-negative breast cancer.</s></p><p><s>Further consideration of the BCAC-iCOGS data found no association for rs115635831 at 2q33 with ER-positive breast cancer (P ¼ 0.23) but identified a significant difference (P diff ¼ 2.9 Â 10 À 4 ) in the per-allele ORs for ER-positive and ER-negative breast cancer (Q-test, Supplementary Table 10).</s><s>No influence of bilateral disease was observed in sensitivity analyses (Supplementary Table <ref type="table" target="#tab_0">11</ref>).</s><s>However, the index SNPs in the 2q33 locus were significantly associated with BRCA1 breast cancer (rs115635831, P ¼ 0.018; rs188686860, P ¼ 0.012; Table <ref type="table" target="#tab_1">2</ref>).</s><s>While there were no significant differences in the associations with ER-positive and ER-negative disease among BRCA1 carriers (PHet ¼ 0.12), the associations were stronger for ER-negative (rs115635831 HR ¼ 1.32, P ¼ 3 Â 10 À 3 ) than ER-positive breast cancer (rs115635831 overall HR ¼ 1.21, P ¼ 0.018) using the retrospective likelihood model (Supplementary Table <ref type="table" target="#tab_1">12</ref>).</s><s>In addition, the associations for BRCA1 mutation carriers were of similar magnitude as the OR estimates for ER-negative breast cancer in BCAC-iCOGS <ref type="bibr" target="#b27">27</ref> (Supplementary Table <ref type="table" target="#tab_0">15</ref>).</s><s>There was also no evidence of intraclass heterogeneity (Po0.05) between the effect estimates for BRCA1 mutation carriers and ER-negative breast cancer in the general population (BCAC-iCOGS) <ref type="bibr" target="#b27">27</ref> .</s><s>A competing risks analysis for BRCA1 mutation carriers found little influence of ovarian cancer on risks of breast cancer (rs115635831 HR ¼ 1.23, P ¼ 0.016), and no evidence of association with ovarian cancer risk using the retrospective likelihood model (Supplementary Table <ref type="table" target="#tab_0">13</ref>).</s><s>No association with overall breast cancer risk among BRCA2 mutation carriers (Supplementary Table <ref type="table" target="#tab_0">10</ref>) was evident.</s><s>Interestingly, rs114962751 at 2q33 and rs150750171 at 6p had the most significant interaction (P ¼ 3.9 Â 10 À 4 ) among all known breast cancer risk SNPs in the iCOGS data, although the interaction was non-significant after adjusting for multiple testing (Supplementary Table <ref type="table" target="#tab_0">14</ref>).</s><s>Altogether these results suggest the presence of a novel locus associated with ER-negative breast cancer that is located in the CLK1/PPIL3 region proximal to CASP8.</s></p><p><s>Expression quantitative trait locus (eQTL) analysis.</s><s>To identify the genes in the novel loci influenced by the observed associations with ER-negative breast cancer, expression quantitative trait locus (eQTL) analyses were performed using gene expression data from breast tumour tissue and normal breast tissue and 1000 Genomes Project imputed SNPs in 1 Mb regions around the novel loci.</s><s>In the 2p23.2</s><s>locus, the strongest cis eQTL associations for 735 TCGA breast tumours (BC765) involved TRMT61B expression (Supplementary Table <ref type="table" target="#tab_0">17</ref>).</s><s>Most of the genome-wide significant ER-negative breast cancer risk SNPs in the locus displayed associations with TRMT61B expression, including the imputed SNPs (rs67073037, P ¼ 1.47 Â 10 À 5 ; Supplementary Fig. <ref type="figure" target="#fig_2">3</ref>; rs6734079, P ¼ 1.85 Â 10 À 5 ) and the genotyped SNP (rs4577254, P ¼ 5.61 Â 10 À 5 ) most significantly associated with risk (Supplementary Table <ref type="table" target="#tab_0">18</ref>).</s><s>Similarly, in a Norwegian normal breast cohort of 116 normal breast tissues (NB116), the strongest cis eQTLs associations involved TRMT61B expression and the risk SNPs in the locus yielded significant associations with TRMT61B expression (Supplementary Table <ref type="table" target="#tab_0">17</ref>).</s><s>While the peak eQTL SNPs (rs6419696, P ¼ 1.21 Â 10 À 17 ) were not among the SNPs showing the greatest association with risk (rs6419696, P ¼ 2.6 Â 10 À 3 ), conditional analyses showed that the rs6419696 wSNPs with more significant associations with ER-negative disease than known index SNPs from these loci.</s></p><p><s>eQTL SNP accounted for much of the influence of the rs4577254 SNP on ER-negative breast cancer risk (P ¼ 9.07 Â 10 À 4 ) and vice versa (Supplementary Table <ref type="table" target="#tab_0">18</ref>).</s><s>Thus, modulation of TRMT61B expression may contribute in part to the risk of breast cancer in this region.</s><s>In the 13q22.1 locus, the strongest eQTLs in the 735 TCGA breast tumours (BC765) involved PIBF1 (Supplementary Table <ref type="table" target="#tab_0">19</ref>).</s><s>However, none of the SNPs strongly associated with breast cancer risk in either of the two independent 13q22 loci showed associations with gene expression (Supplementary Table <ref type="table" target="#tab_0">19</ref>, Supplementary Fig. <ref type="figure">4</ref>).</s><s>In contrast, significant associations with DIS3 expression were observed in the BC241 and NB116 cohorts for many of the genome-wide significant SNPs in the locus represented by rs17181761 (NB116 eQTL P ¼ 2.34 Â 10 À 3 ) (Supplementary Table <ref type="table" target="#tab_0">19</ref>).</s><s>While nonsignificant after accounting for multiple testing, these observations suggest that future studies should evaluate mechanistic interactions between 13q22.1 SNPs and DIS3 expression.</s><s>Evaluation of eQTLs in the 2q33 locus for the BC765 cohort found that many of the 157 risk-associated SNPs (Table <ref type="table" target="#tab_1">2</ref>, Supplementary Table <ref type="table" target="#tab_0">15</ref>) had strong associations with PPIL3 expression (rs188686860, P ¼ 1.77 Â 10 À 7 ; rs115635831, P ¼ 6.08 Â 10 À 7 ; Supplementary Fig. <ref type="figure">5</ref>) and little evidence of any associations with other genes in the region (Supplementary Table <ref type="table" target="#tab_1">20</ref>).</s><s>This is one of the few known breast cancer risk loci where the most significant risk SNPs are strongly associated with local gene expression.</s><s>PPIL3 is located at the proximal end of the locus, 270 kb upstream of CASP8, further suggesting that the 2q33 risk locus is independent of any influence on CASP8.</s></p><p><s>Functional characterization of the 2p23.2</s><s>locus.</s><s>To identify candidate SNPs and genes in the 2p23.2</s><s>locus driving ER-negative breast cancer risk, ENCODE chromatin biofeatures were evaluated in primary human mammary epithelial cells (HMECs), MCF7 ER-positive cells and MB-MDA-231 ER-negative cells <ref type="bibr" target="#b30">30</ref> .</s><s>Sixteen of the 79 most significantly associated SNPs (Po3 Â 10 À 7 ) in the region overlapped with three distinct regulatory regions (Supplementary Figs <ref type="figure">6 and 7</ref>).</s><s>The most significantly associated ER-negative SNP, rs67073037 (Table <ref type="table" target="#tab_1">2</ref>) was located in intron 1 of WDR43 near the transcription start site in a region containing acetylated H3K27 and trimethylated H3K4 chromatin marks in normal HMECs and MB-MDA-231 ER-negative breast tumour cells, and a DNase hypersensitivity cluster in ER-positive MCF7 cells (Supplementary Figs <ref type="figure">6 and 7</ref>).</s></p><p><s>The three risk-associated SNPs (rs4407214, rs66604446 and rs66768547) with the most significant RegulomeDB scores (2b), were located in the same chromatin marks in this region in HMEC, MD-MBA-231 and MCF7 cells (http://regulomedb.org).</s></p><p><s>In addition, the top genotyped SNP (rs4577244) was located in a monomethylated H3K4 mark adjacent to the core promoter region of WDR43 in HMECs (Supplementary Fig. <ref type="figure">6</ref>).</s><s>Separately rs11677283 and rs35617956 in introns 9 and 10 of WDR43 were located in acetylated H3K27 and H3K9 chromatin marks in a putative regulatory region in HMECs, but not in ER-negative MD-MBA-231 cells.</s></p><p><s>Combining the eQTL results with these predictions, we tested four genomic tiles spanning region 1 for enhancer activity in both orientations using a luciferase reporter assay in the CAL51 ERnegative breast cancer line and MCF10A normal mammary epithelial cells (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>The tile containing rs4407214 displayed significant enhancer activity (Po0.0001) in at least one orientation when compared with the negative control in MCF10A and CAL51 (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>In addition, the tile carrying the diseaseassociated G allele showed significantly (P ¼ 0.0059) higher activity than the T allele in MCF10A cells (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>Similarly, the disease-associated G-allele showed significantly (P ¼ 0.0059) higher activity than the T-allele in a luciferase-based promoter assay in MCF10A cells (P ¼ 0.044) and CAL51 (P ¼ 0.0078; Supplementary Fig. <ref type="figure">8</ref>).</s><s>Consistent with these allele-specific changes in transcriptional activity different protein complexes in electrophoretic mobility shift assays were observed using CAL51 and MCF10A nuclear extracts (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>In addition, Pol2 ChIA-PET in MCF7 breast cancer cells revealed an interaction between Region 1 and the promoter of TRMT61B (Fig. <ref type="figure" target="#fig_2">3</ref>), which had the strongest eQTL signal in the locus.</s><s>These results are consistent with modification of Pol2 binding to this region by rs4407214 in lymphoblastoid cells <ref type="bibr" target="#b31">31</ref> and suggest the presence of a transcriptional enhancer in the region.</s><s>Separately, the ChIA-PET data further suggest that Region 2 in WDR43 may interact with the promoter of WDR43 (Fig. <ref type="figure" target="#fig_2">3</ref>).</s><s>Thus, WDR43 and TRMT61B may be regulated by interactions of enhancers in WDR43 with the core WDR43 and TRMT61B promoters and may jointly influence breast cancer risk in this region.</s></p><p><s>Functional characterization of the 13q22 locus.</s><s>The SNPs most significantly associated with ER-negative breast cancer in the two 13q22 loci formed two small clusters in a 4-kb region around rs17181761 and a 10-kb region around rs8002929.</s><s>Bioinformatics analysis and chromatin feature analysis identified weak DNaseI hypersensitivity sites, CTCF binding and monomethylated H3K4 sites in both regions in HMEC cells, consistent with weak enhancer activity (Supplementary Figs 9 and 10).</s><s>Both rs17181761 and rs12870942 in the proximal locus are associated with transcriptional activity in HMECs, whereas rs8002929 and rs927683 in the distal locus are associated with enhancer and DNAse hypersensitivity sites in HMECs, respectively (http://regulomedb.org).</s><s>Both 13q22 loci are located in a non-genic 600-kb region between the KLF5 and KLF12 kruppel-like transcription factor genes.</s><s>This segment of chromosome 13 is frequently deleted in a spectrum of cancers <ref type="bibr" target="#b32">32,</ref><ref type="bibr" target="#b33">33</ref> .</s><s>GWAS have also identified a pancreatic cancer risk locus in the region between KLF5 and KLF12 (refs 34-36).</s><s>However, the rs9543325 SNP from the pancreatic cancer studies was only marginally associated with ER-negative breast cancer risk (P ¼ 0.03) in the meta-analysis suggesting that the signals are independent.</s></p><p><s>Functional characterization of the 2q33 locus.</s><s>The SNPs most significantly associated with ER-negative breast cancer in the 2q33 locus range across a 350-kb region that contains nine genes (Supplementary Fig. <ref type="figure">6</ref>).</s><s>This region contains at least 10 strong enhancer regions in HMECs and 12 strong enhancer regions in MD-MBA-231 cells associated with acetylated H3K27 and trimethylated H3K4 chromatin marks.</s><s>As noted above, many of the 157 SNPs most significantly associated with ER-negative breast cancer are associated with PPIL3 expression.</s><s>Seven of these also scored as functional candidates by RegulomeDB (score ¼ 3a; rs17467658, rs17383256, rs17467916, rs114567273, rs76377168, rs116509920 and rs116724456).</s><s>Of these rs17467658 in CLK1 and rs17383256 in the ORC2 gene are located in DNAse hypersensitivity sites and strong enhancer regions in HMEC and MD-MBA-231 cells (http://www.roadmapepigenomics.org; Supplementary Figs <ref type="figure" target="#fig_1">11 and  12</ref>).</s><s>In addition, rs116509920 and rs116724456 are associated with PPIL3 expression (P ¼ 5.85 Â 10 À 7 ), although neither SNP is associated with an enhancer or suppressor region.</s><s>The genotyped SNP most significantly associated with risk, rs114962751, is located in acetylated H3K27 and trimethylated H3K4 chromatin marks in a bidirectional promoter for FAM126B and NDUFB3 in HMEC and MD-MBA-231 cells (Supplementary Figs <ref type="figure" target="#fig_1">11 and 12</ref>).</s><s>Similarly, the rs74943274 genotyped risk SNP (Table <ref type="table" target="#tab_1">2</ref>) is located near the 3 0 -untranslated region of CLK1 and is associated with PPIL3 expression (P ¼ 2.37 Â 10 À 6 ).</s><s>However, rs78258606 is perhaps a more likely candidate driver of ER-negative risk in this locus because the SNP is associated with ER-negative breast cancer (P ¼ 1.9 Â 10 À 7 ), is located in the CLK1 promoter in acetylated H3K27 and trimethylated H3K4 chromatin marks in HMEC and MD-MBA-231 cells and DNase hypersensitivity sites in MCF7 cells, and is associated with PPIL3 expression (P ¼ 2.71 Â 10 À 7 ) (Supplementary Figs <ref type="figure" target="#fig_1">11 and 12</ref>).</s><s>Further fine mapping and functional characterization of this locus is needed to resolve the underlying functional effects and identify the genes influencing ER-negative breast cancer risk.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>When including the four 2p23.2,</s><s>13q22 and 2q33 novel loci identified in this meta-analysis, 23 independent loci have shown genome-wide significant associations with ER-negative disease, including 10 loci showing no associations or only weak associations with ER-positive disease.</s><s>In total, 63 loci have shown at least marginal significance (Po0.05) with ER-negative breast cancer.</s><s>In BRCA1 mutation carriers, 27 independent loci (Po0.05) have been associated with modified breast cancer risk <ref type="bibr" target="#b27">27</ref> .</s><s>The percentage of the familial risk for ER-negative disease explained by SNPs is not well defined because there is currently no good estimate for the familial relative risk for ER-negative disease.</s><s>However, assuming that the estimate is similar to that for overall breast cancer (twofold for a first-degree relative), and based on the estimated frequencies and ORs from the iCOGS data, the SNPs in the known breast cancer risk loci explain 9.8% of the familial risk and the SNPs in the four new loci account for a further 0.8%.</s><s>The addition of these new ER-negative loci may improve overall risk prediction models for ER-negative disease in the general population and for breast cancer among BRCA1 mutation carriers by enhancing the contribution of current polygenic risk prediction models <ref type="bibr" target="#b20">21,</ref><ref type="bibr" target="#b21">22</ref> .</s><s>Furthermore, fine mapping and functional studies of these loci may provide further insight into the aetiology of ER-negative breast cancer.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p><s>Study populations.</s><s>Details of the subjects, genotyping and quality control measures for the BCAC GWAS and iCOGS data <ref type="bibr" target="#b2">3</ref> , BPC3 (ref.</s><s>16), EBCG <ref type="bibr" target="#b37">37</ref> , TNBCC <ref type="bibr" target="#b13">14,</ref><ref type="bibr">38</ref>  Genotype data.</s><s>Genotyping and imputation details for each study are shown in Supplementary Table <ref type="table" target="#tab_0">1</ref>.</s></p><p><s>Imputation.</s><s>We performed imputation separately for BRCA1 carriers, 11 GWAS, BCAC-iCOGS and TNBCC-iCOGS samples.</s><s>We imputed variants from the 1000 Genomes Project data using the v3 April 2012 release <ref type="bibr" target="#b39">39</ref> as the reference panel.</s><s>Imputation was based on the 1000 Genomes Project data with singletons removed.</s><s>Eight BCAC GWAS were imputed in a two-step procedure, with prephasing using the SHAPEIT software and imputation of the phased data in the second with IMPUTEv2 (ref.</s><s>40).</s><s>For the remaining three GWAS (BPC3, TNBCC and EBCG), imputation was performed using MACH (version 1.0.18) and Minimac (version 2012.8.15) <ref type="bibr" target="#b41">41</ref> .</s><s>The iCOGS data were also imputed with two-stage procedure involving SHAPEIT and IMPUTEv2.</s><s>To perform the imputation we divided the data into segments of B5 Mb each.</s><s>The iCOGS samples were divided into 10 subsets, keeping all subjects from individual studies in the same set.</s><s>Estimates and s.e.'s were obtained using logistic regression adjusting for study and 9 principal components.</s><s>GWAS SNPs were excluded if the imputation accuracy was r 2 o0.3 or if the minor allele frequency (MAF) was o0.01, TNBCC SNPs were excluded when the imputation accuracy was r 2 o0.9 and MAFo0.05,</s><s>iCOGS SNPs were excluded when r 2 o ¼ 0.3 and MAFo0.005.</s><s>Regions with evidence of genome-wide significant associations (Po5 Â 10 À 8 ) were reimputed in iCOGS, using IMPUTEv2 but without prephasing in SHAPEIT to improve imputation accuracy.</s></p><p><s>In addition, the number of MCMC iterations were increased from 30 to 90, and the buffer region was increased to ±500 kb from any significantly associated SNP in the region.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Meta-analysis.</head><p><s>A fixed effects meta-analysis of ER-negative breast cancer associations was conducted using an inverse variance approach assuming fixed effects, as implemented in METAL <ref type="bibr" target="#b42">42</ref> .</s><s>The effect estimates used were the logarithm of the per-allele HR estimate for the association with breast cancer risk in BRCA1 and BRCA2 mutation carriers and the logarithm of the per-allele OR estimate for the association with breast cancer status in GWAS and iCOGS analyses, both of which were assumed to approximate the same relative risk.</s><s>For the associations in BRCA1 mutation carriers, a kinship-adjusted variance estimator was used <ref type="bibr" target="#b11">12</ref> .</s><s>P-values were estimated by z-test.</s></p><p><s>Heterogeneity analysis.</s><s>Heterogeneity across estimates from BCAC and iCOGS were evaluated using a Cochran Q test and I 2 for the proportion of total variability explained by heterogeneity in the effect sizes <ref type="bibr" target="#b43">43</ref> .</s><s>Associations with ER-positive and ER-negative subgroups of BRCA1 carriers were evaluated using an extension of the retrospective likelihood approach to model the simultaneous effect of each SNP on more than one tumour subtype <ref type="bibr" target="#b27">27</ref> .</s><s>The consistency between breast cancer associations for breast cancer susceptibility variants in the general population and associations in BRCA1 and BRCA2 carriers were evaluated using the intraclass correlation (ICC) <ref type="bibr" target="#b27">27</ref> .</s><s>The ICC was estimated based on a one-way random-effects model and tested for agreement in absolute values of log HR.</s></p><p><s>Locus coverage.</s><s>Locus boundaries were defined so that all SNPs with r 2 Z0.1 with the most significantly associated SNP were included.</s><s>SNPs with MAFo0.005 were excluded.</s><s>Linkage disequilibrium blocks were defined at r 2 Z0.8.</s><s>Each linkage disequilibrium block was evaluated for the presence of at least one genotyped or imputed SNP.</s><s>If imputed, then the imputation accuracy was considered.</s></p><p><s>Expression quantitative trait locus analysis.</s><s>eQTL analysis was performed for all protein coding genes within 1 Mb, up-and downstream of the SNP most significantly associated with ER-negative breast cancer risk in each locus.</s><s>Normal breast (NB116; n ¼ 116) and breast cancer (BC241, n ¼ 241) are comprised of women of Norwegian descent.</s><s>Gene expression data for the majority of women in NB116 were derived from normal breast tissue in women who had not been affected with breast cancer; data for ten women were derived from normal tissue adjacent to a tumour.</s><s>Gene expression data for BC241 were derived from breast tumours (70 ER-negative and 170 ER-positive).</s><s>Genotyping was performed with the iCOGS SNP array, and gene expression levels were measured with the Agilent 44K array <ref type="bibr" target="#b44">44,</ref><ref type="bibr" target="#b45">45</ref> .</s><s>BC765 (n ¼ 765) is the TCGA breast cancer cohort composed of 139 ER-negative, 571 ER-positive and 55 undefined breast tumours; all non-European samples (as determined by clustering and PCA) were excluded from this analysis <ref type="bibr" target="#b46">46</ref> .</s><s>Germline genotype data from Affymetrix SNP 6 array were obtained from TCGA dbGAP data portal <ref type="bibr" target="#b46">46</ref> .</s><s>Gene expression levels for the breast tumours were assayed by RNA sequencing, RSEM (RNaseq by Expectation-Maximization21) normalized per gene, as obtained from the TCGA consortium portal <ref type="bibr" target="#b46">46</ref> .</s><s>The data were log2 transformed, and unexpressed genes were excluded prior to eQTL analysis.</s><s>There is no overlap between women recruited to each of these studies.</s><s>The genotyping data were processed as follows: SNPs with call rates o0.95 or minor allele frequencies o0.05 or Hardy-Weinberg equilibrium (Po10 À 13 ) were excluded.</s><s>Samples with call rates below 80% were excluded.</s></p><p><s>Identity by state was computed with the R GenABEL package <ref type="bibr" target="#b47">47</ref> and closely related samples with IBS40.95 were removed.</s><s>Imputation was performed on the iCOGS and Affymetrix6 germline genotype data using the 1000 Genomes Project March 2012 v.3 release as the reference data set.</s><s>A two-stage imputation procedure was used as described above.</s><s>The influence of SNPs on gene expression was assessed using a linear regression model.</s><s>An additive effect was assumed by modelling copy number of the rare allele, that is, 0, 1 or 2, for a given genotype.</s></p><p><s>Candidate gene analysis.</s><s>TCGA has performed extensive genomic analysis of tumours from a large number of tissue types including over 1,000 breast tumours.</s></p><p><s>All genes in the novel loci were evaluated for coding somatic sequence variants in TCGA.</s><s>Breast tumours with log2 copy-number data in the TCGA data were analysed for deletion and amplification of each candidate gene using the cBio portal <ref type="bibr" target="#b48">48,</ref><ref type="bibr" target="#b49">49</ref> .</s></p><p><s>Informatics and chromatin biofeatures.</s><s>Candidate SNPs were evaluated using SNPInfo (http://snpinfo.niehs.nih.gov) and SNPnexus (http://snp-nexus.org/test/</s><s>snpnexus).</s><s>The presence of SNPs in transcription factor binding sites using TRANSFAC and miRNA binding sites using TargetScan were noted.</s><s>Regulatory potential scores (ESPERR Regulatory Potential) were obtained from the UCSC genome bioinformatics browser (http://genome.ucsc.edu/).</s><s>RegulomeDB (http:// regulomedb.org) was used to assess SNPs for transcription factor recognition motifs, open chromatin structure based on FAIRE and DNAse-seq analysis and protein binding sites based on ChIP-seq data.</s><s>Chromatin biofeatures in HMEC and MCF7 cells were assessed using ENCODE layers on the UCSC browser (http:// genome.ucsc.edu/).</s><s>Enhancers active in the mammary cell types MCF7 and HMEC were cross-referenced with candidate SNPs.</s></p><p><s>Luciferase reporter assays.</s><s>Genomic tiles spanning regions containing SNPs with indication of regulatory activity by RegulomeDB were generated.</s><s>Regions containing the major and minor alleles within the 2p23.2</s><s>region spanning 2,229 bp (chr2:29,117,333-29,119,561) were generated by PCR using BAC DNA CTD-3216P10 as template.</s><s>Forward and reverse primers contained attB1 and attB2 sequences, respectively, to aid in recombinational cloning.</s><s>Tiles were cloned in both a forward and reverse orientation upstream of the SV40 promoter by recombination in the firefly luciferase reporter vector pGL3-Pro-attb vector designed to test for enhancer regions.</s><s>This vector is a modification of pGL3-Promoter (Invitrogen) adding attB sites surrounding the ccdb gene.</s><s>The clone containing the tile was co-transfected in eight replicates using LipoFectamine 2000 (Life Technologies) into MCF10A or CAL51 cells with pRL-CMV (Promega), an internal control expressing Renilla luciferase, per well of 96-well plates.</s><s>Luciferase activity was measured 24-h post transfection by Dual Glo Luciferase Assay (Promega).</s><s>Transfections were repeated in two independent experiments with similar results.</s><s>The influence of the common and rare alleles of rs4407214 on promoter activity in the pGL3-Promoter vector (Invitrogen) were assessed using the same methodology.</s><s>Primers are available on request.</s></p><p><s>Electromobility shift assays.</s><s>Nuclear proteins from MCF10A and CAL51 cells were extracted using a hypotonic lysis buffer (10 mM HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCL) supplemented with DTT and protease inhibitors, followed by an extraction buffer (20 mM HEPES, ph 7.9, 1.5 mM MgCl 2 , 0.42 M NaCl, 0.2 mM EDTA, 25% v/v glycerol) supplemented with DTT and protease inhibitors.</s><s>Electrophoretic mobility shift assays probes were designed to cover each SNP ± 20 base pairs, for both major and minor alleles.</s><s>Probe pairs were dissolved in water and annealed at a concentration of 10 mM each.</s><s>Probes were labelled with ATP (g-32 P; Perkin Elmer) using T4 polynucleotide kinase and cleaned using the QiaQuick Nucleotide Removal Kit (Qiagen).</s><s>Labelled and unlabelled probes were then incubated with protein extracts using LightShift Poly(dI-dC) (Thermo) and a binding buffer (10 mM Tris, 50 mM KCl, 1 mM DTT, pH 7.4) and electrophoresed on a 6% acrylamide gel overnight at 83 V. Gels were dried and films were exposed for 4-24 h.</s><s>Probe sequences are shown in Supplementary Table <ref type="table" target="#tab_1">21</ref>.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 |</head><label>1</label><figDesc><div><p><s>Figure 1 | Manhattan plot of ER-negative breast cancer meta-analysis.</s><s>The Manhattan plot displays the strength of genetic association ( À log 10 P) versus chromosomal position (Mb), where each dot presents a genotyped or imputed (black circle) SNP.</s><s>The black horizontal line represents the threshold for genome-wide significance (P ¼ 5 Â 10 À 8 ).</s></p></div></figDesc><graphic coords="2,72.89,464.29,213.74,198.02" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 |</head><label>2</label><figDesc><div><p><s>Figure 2 | Novel ER-negative breast cancer loci.</s><s>The chromosomal position and strength of genetic association ( À log 10 P) is shown for all SNPs (Po1 Â 10 À 6 ) in BCAC/iCOGS data in the four novel risk loci.</s><s>(a).</s><s>2p23 locus.</s><s>The most significant SNP (rs67073037) is shown as a diamond.</s><s>(b).</s><s>13q22 loci.</s><s>The most significant SNP (rs6562760) is shown as a diamond.</s><s>The second locus is shown in black.</s><s>(c).</s><s>2q33 locus.</s><s>The most significant SNPs (rs188686860; rs115635831) are shown as diamonds.</s></p></div></figDesc><graphic coords="3,196.85,250.69,211.98,154.34" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 |</head><label>3</label><figDesc><div><p><s>Figure 3 | The chromatin landscape of locus 2p23.2.</s><s>(a) The SNP rs4407214 is included in a genomic tile overlapping chromatin features indicative of promoters and enhancers, shaded red.</s><s>(b,c).</s><s>Luciferase assays showing activity in the tile containing SNP rs4407214 (highlighted in pink in a.) in MCF10A and CAL51, red box plots indicate significantly different from the control tile (Po0.0001).</s><s>Brown box plot indicates significant difference from the reference allele (P ¼ 0.0059).</s><s>(d) Electrophoretic mobility shift assay (EMSA) showing the formation of allele-specific complexes for rs4407214.</s><s>M, major allele; m, minor allele.</s><s>Lines 1, 2, 7, 8-no nuclear extract.</s><s>Lines 3, 4, 5, 6-10 mg of MCF10A nuclear extract.</s><s>Lines 9, 10, 11, 12-10 mg of CAL51 nuclear extract.</s><s>Shift detected by comparison to bands (arrows #1 and #2).</s></p></div></figDesc><graphic coords="4,453.53,355.45,86.08,109.82" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 |</head><label>1</label><figDesc><div><p><s>Common genetic variants from known breast cancer susceptibility loci displaying most significant genome-wide associations with ER-negative breast cancer risk.</s></p></div></figDesc><table><row><cell>Location</cell><cell>Position</cell><cell>Nearest</cell><cell>SNP</cell><cell>Alleles</cell><cell>iCOGS/GWAS ER-negative</cell><cell></cell><cell></cell><cell>BRCA1 carriers</cell><cell>Meta-analysis</cell></row><row><cell></cell><cell></cell><cell>gene</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>EAF</cell><cell>OR (95% CI)</cell><cell>P</cell><cell>EAF</cell><cell>HR (95% CI)</cell><cell>P</cell><cell>P *</cell></row><row><cell cols="5">Variants in known loci most significantly associated with overall breast cancer w 1p36.2 10563609 PEX14 rs10864459 G/A 0.32 w 1q32.1 202179042 LGR6 rs17489300 A/C 0.4 1q32.1 204518842 MDM4 rs4245739 A/C 0.26 2p24.1 19184284 2p24.1 rs12710696 C/T 0.36 w 2q14.2 121088182 INHBB rs11903787 G/A 0.25 w 5p15.3 1280028 TERT rs2242652 A/G 0.20 5p15.3 1282319 TERT rs7726159 A/C 0.34 5p15.3 1297488 TERT rs2736108 T/C 0.29 6q25.1 151918856 ESR1 rs12662670 T/G 0.08 w 6q25.1 151946152 ESR1 rs11155804 A/T 0.34 10q21.2 64278682 ZNF365 rs10995190 G/A 0.16 w 10q25.2 114782803 TCF7L2 rs6585202 T/C 0.46 w 11p15.5 1902097 LSP1 rs4980383 C/T 0.44 w 12p11.2 28174817 PTHLH rs7297051 C/T 0.24 12p11.2 28155080 PTHLH rs10771399 A/G 0.12 w 16q12.1 52599188 TO Â 3 rs4784227 C/T 0.24 16q12.2 53813367 FTO rs17817449 T/G 0.41 16q12.2 53855291 FTO rs11075995 T/A 0.24 19p13.1 17389704 MERIT40 rs8170 G/A 0.19 w 19p13.1 17393925 ADHB8 rs56069439 C/A 0.30</cell><cell cols="2">0.90 (0.87-0.93) 2.13 Â 10 À 9 0.90 (0.87-0.93) 9.37 Â 10 À 10 1.13 (1.11-1.19) 5.53 Â 10 À 15 1.10 (1.06-1.13) 1.70 Â 10 À 8 0.90 (0.86-0.94) 8.57 Â 10 À 7 1.18 (1.13-1.23) 2.73 Â 10 À 14 1.09 (1.05-1.13) 2.19 Â 10 À 6 0.89 (0.86-0.93) 1.41 Â 10 À 8 1.20 (1.18-1.32) 8.90 Â 10 À 15 1.16 (1.12-1.19) 8.18 Â 10 À 18 0.89 (0.85-0.93) 3.75 Â 10 À 8 1.06 (1.04-1.10) 3.35 Â 10 À 5 1.08 (1.05-1.12) 3.02 Â 10 À 6 0.86 (0.83-0.89) 1.48 Â 10 À 14 0.79 (0.78-0.87) 3.82 Â 10 À 13 1.15 (1.11-1.19) 1.11 Â 10 À 14 0.91 (0.89-0.95) 2.83 Â 10 À 7 1.11 (1.07-1.15) 3.30 Â 10 À 8 1.15 (1.11-1.20) 1.35 Â 10 À 12 1.16 (1.13-1.20) 8.25 Â 10 À 19</cell><cell cols="2">0.31 0.39 0.97 (0.93-1.01) 0.95 (0.91-0.99) 0.28 1.09 (1.05-1.14) 0.39 1.01 (0.97-1.05) 0.26 0.91 (0.87-0.96) 0.22 1.22 (1.16-1.28) 0.35 1.07 (1.02-1.11) 0.29 0.89 (0.86-0.93) 4.05 Â 10 À 7 0.01 0.19 6.83 Â 10 À 5 0.56 2.0 Â 10 À 4 2.53 Â 10 À 15 7.58 Â 10 À 28 4.60 Â 10 À 10 1.98 Â 10 À 8 7.71 Â 10 À 18 1.90 Â 10 À 6 7.24 Â 10 À 10 1.79 Â 10 À 3 3.31 Â 10 À 8 3.05 Â 10 À 14 0.09 1.19 (1.11-1.27) 9.67 Â 10 À 7 1.32 Â 10 À 19 0.36 1.15 (1.11-1.20) 0.02 3.75 Â 10 À 28 0.16 0.99 (0.94-1.04) 0.66 8.23 Â 10 À 6 0.47 1.10 (1.05-1.14) 6.08 Â 10 À 6 1.32 Â 10 À 9 0.45 1.07 (1.03-1.11) 7.73 Â 10 À 4 9.41 Â 10 À 9 0.23 0.89 (0.85-0.93) 2.89 Â 10 À 7 3.12 Â 10 À 20 0.10 0.86 (0.80-0.91) 2.55 Â 10 À 6 7.18 Â 10 À 18 0.26 1.07 (1.02-1.12) 4.97 Â 10 À 3 6.44 Â 10 À 15 0.41 0.95 (0.92-0.99) 0.02 5.26 Â 10 À 8 0.24 1.01 (0.97-1.06) 0.61 1.56 Â 10 À 6 0.19 1.17 (1.11-1.23) 7.29 Â 10 À 10 6.64 Â 10 À 21 0.30 1.19 (1.14-1.24) 1.42 Â 10 À 15 1.49 Â 10 À 32</cell></row></table><note><p><s>CI, confidence interval; EAF, effect allele frequency; ER, oestrogen receptor; GWAS, genome-wide association studies; HR, hazard ratio; OR, odds ratio; SNP, single-nucleotide polymorphism.</s><s>*P values from iCOGS/BCAC and meta-analysis for ER-negative breast cancer were estimated by z-test.</s><s>P values for BRCA1 carriers were estimated by a kinship-adjusted retrospective likelihood approach.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 |</head><label>2</label><figDesc><div><p><s>Novel associations of common genetic variants with ER-negative breast cancer risk.</s><s>Effect allele frequency; ER, oestrogen receptor; GWAS, genome-wide association studies; HR, hazard ratio; OR, odds ratio; r 2 , imputation accuracy; SNP, single-nucleotide polymorphism.</s><s>*P values from iCOGS/BCAC and meta-analysis for ER-negative breast cancer were estimated by z-test.</s><s>P values for BRCA1 carriers were estimated by a kinship-adjusted retrospective likelihood approach.</s></p></div></figDesc><table><row><cell>iCOGS/GWAS ER-negative</cell><cell>BRCA1 carriers</cell><cell>Meta-analysis</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head></head><label></label><figDesc><div><p><s>and BRCA1 (ref.22) are described elsewhere.</s><s>Analyses were restricted to women of European ancestry.</s><s>Overall, 42 BCAC studies provided the iCOGS genotyping data for ER-negative breast cancer cases and controls.</s><s>In addition, 11 breast cancer studies provided GWAS genotyping data.</s><s>Forty five CIMBA studies provided iCOGS genotyping on 15,252 BRCA1 mutation carriers, of whom 7,797 were affected with breast cancer.</s></p></div></figDesc><table /></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">NATURE COMMUNICATIONS | 7:11375 | DOI: 10.1038/ncomms11375 | www.nature.com/naturecommunications</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Acknowledgements</head><p><s>We thank all the researchers and administrative staff who have enabled this work to be carried out and all of the individuals who took part in these studies.</s></p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Author contributions</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Additional information</head><p><s>Supplementary Information accompanies this paper at http://www.nature.com/</s><s>naturecommunications Competing financial interests: The authors declare no competing financial interests.</s></p><p><s>Reprints and permission information is available online at http://npg.nature.com/</s><s>reprintsandpermissions/</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world</title>
		<author>
			<persName><forename type="first">F</forename><surname>Kamangar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Dores</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">F</forename><surname>Anderson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Clin. Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="2137" to="2150" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">A comprehensive evaluation of family history and breast cancer risk. The Utah Population Database</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Slattery</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Kerber</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">270</biblScope>
			<biblScope unit="page" from="1563" to="1568" />
			<date type="published" when="1993">1993</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Large-scale genotyping identifies 41 new loci associated with breast cancer risk</title>
		<author>
			<persName><forename type="first">K</forename><surname>Michailidou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="353" to="361" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Genome-wide association study identifies novel breast cancer susceptibility loci</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Easton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">447</biblScope>
			<biblScope unit="page" from="1087" to="1093" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Hunter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="870" to="874" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Stacey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="865" to="869" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">N</forename><surname>Stacey</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="703" to="706" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ahmed</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="585" to="590" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Genome-wide association study identifies a new breast cancer susceptibility locus at 6q25.1</title>
		<author>
			<persName><forename type="first">W</forename><surname>Zheng</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="324" to="328" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1)</title>
		<author>
			<persName><forename type="first">G</forename><surname>Thomas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="579" to="584" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Genome-wide association study identifies five new breast cancer susceptibility loci</title>
		<author>
			<persName><forename type="first">C</forename><surname>Turnbull</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="504" to="507" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Antoniou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="885" to="892" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Novel breast cancer susceptibility locus at 9q31.2: results of a genome-wide association study</title>
		<author>
			<persName><forename type="first">O</forename><surname>Fletcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J.N.C.I</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="page" from="425" to="435" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Haiman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1210" to="1214" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Genome-wide association analysis identifies three new breast cancer susceptibility loci</title>
		<author>
			<persName><forename type="first">M</forename><surname>Ghoussaini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="312" to="318" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11</title>
		<author>
			<persName><forename type="first">A</forename><surname>Siddiq</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Mol. Genet</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="5373" to="5384" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Genome-wide association studies identify four ER negative-specific breast cancer risk loci</title>
		<author>
			<persName><forename type="first">M</forename><surname>Garcia-Closas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="398" to="e399" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Bojesen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="371" to="384" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Purrington</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Carcinogenesis</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="1012" to="1019" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer</title>
		<author>
			<persName><forename type="first">K</forename><surname>Michailidou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="373" to="380" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">C</forename><surname>Antoniou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">R33</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Couch</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS Genet</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">e1003212</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)</title>
		<author>
			<persName><forename type="first">N</forename><surname>Mavaddat</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol. Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="134" to="147" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Lakhani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J. Natl Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="1138" to="1145" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Lakhani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin. Cancer Res</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="5175" to="5180" />
			<date type="published" when="2005">2005</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the</title>
		<author>
			<persName><forename type="first">G</forename><surname>Chenevix-Trench</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA)</title>
				<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">104</biblScope>
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Kuchenbaecker</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Breast Cancer Res</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">3416</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">A genome-wide association scan (GWAS) for mean telomere length within the COGS project: identified loci show little association with hormone-related cancer risk</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">A</forename><surname>Pooley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Mol. Genet</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="5056" to="5064" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Lin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hum. Mol. Genet</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="285" to="298" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Nucleosome positioning and histone modifications define relationships between regulatory elements and nearby gene expression in breast epithelial cells</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Rhie</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Genomics</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page">331</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Variation in transcription factor binding among humans</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kasowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">328</biblScope>
			<biblScope unit="page" from="232" to="235" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Defining a common region of deletion at 13q21 in human cancers</title>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Chromosomes Cancer</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="page" from="333" to="344" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus</title>
		<author>
			<persName><forename type="first">T</forename><surname>Kainu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Proc. Natl Acad. Sci. USA</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page" from="9603" to="9608" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">M</forename><surname>Petersen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="224" to="228" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Wolpin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="994" to="1000" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Childs</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="911" to="916" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">A genome-wide association study of early-onset breast cancer identifies PFKM as a novel breast cancer gene and supports a common genetic spectrum for breast cancer at any age</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ahsan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol. Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="658" to="669" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">1 is a triple-negative-specific breast cancer susceptibility locus</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">N</forename><surname>Stevens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1795" to="1803" />
			<date type="published" when="2012">19p13. 2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">An integrated map of genetic variation from 1,092 human genomes</title>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">491</biblScope>
			<biblScope unit="page" from="56" to="65" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Fast and accurate genotype imputation in genome-wide association studies through pre-phasing</title>
		<author>
			<persName><forename type="first">B</forename><surname>Howie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fuchsberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Stephens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Marchini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Abecasis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="955" to="959" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Newly identified loci that influence lipid concentrations and risk of coronary artery disease</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Willer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="161" to="169" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">METAL: fast and efficient meta-analysis of genomewide association scans</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Willer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Abecasis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="2190" to="2191" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Quantifying heterogeneity in a meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Higgins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Thompson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Stat. Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1539" to="1558" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">The 5p12 breast cancer susceptibility locus affects MRPS30 expression in estrogen-receptor positive tumors</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Quigley</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mol. Oncol</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="273" to="284" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low features</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">D</forename><surname>Haakensen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Med. Genomics</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">77</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Comprehensive molecular portraits of human breast tumours</title>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">490</biblScope>
			<biblScope unit="page" from="61" to="70" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
	<note>Cancer Genome Atlas Network</note>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">GenABEL: an R library for genome-wide association analysis</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Aulchenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ripke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Isaacs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Van Duijn</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="1294" to="1296" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal</title>
		<author>
			<persName><forename type="first">J</forename><surname>Gao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci. Signal</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">1</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</title>
		<author>
			<persName><forename type="first">E</forename><surname>Cerami</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="401" to="404" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Curtis Olswold 2 , Emily Hallberg 2 , Simona Agata 6</title>
		<author>
			<persName><forename type="first">*</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Karoline</forename><forename type="middle">B</forename><surname>Kuchenbaecker 3</surname></persName>
		</author>
		<author>
			<persName><forename type="first">*</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Kyriaki</forename><surname>Michailidou 3</surname></persName>
		</author>
		<author>
			<persName><forename type="first">*</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Gustavo</forename><forename type="middle">A</forename><surname>Mendoza</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Matthias W. Beckmann</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">24</biblScope>
			<publisher>Hermann Brenner 15</publisher>
		</imprint>
	</monogr>
	<note>Jenny Chang-Claude. Stephen J. Chanock 39 , Wendy K. Chung 40 , Kathleen B. M. Claes</note>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Josef Herzog 91 , Frans B.L Hogervorst 92 , Antoinette Hollestelle 93</title>
	</analytic>
	<monogr>
		<title level="m">Uffe Birk Jensen 102 , Esther M. John 103 , Michael Jones</title>
				<editor>
			<persName><forename type="first">A</forename><forename type="middle">E M</forename><surname>Robert</surname></persName>
		</editor>
		<editor>
			<persName><surname>Tollenaar</surname></persName>
		</editor>
		<meeting><address><addrLine>Steve Ellis; Ute Hamann; Steven Hart 2 , Sue Healey; Brian E. Henderson; Kathleen E. Malone; Austin Miller 126 , Roger L. Milne; Anna M. Mulligan; Mary B. Terry; Helen Tsimiklis; Alex Teule ´175 , Rosario Tumino; Clare Turnbull; Alice Whittemore</addrLine></address></meeting>
		<imprint>
			<publisher>Penny Soucy</publisher>
			<date>Jan Lubinski 83</date>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page">184</biblScope>
		</imprint>
	</monogr>
	<note type="report_type">Kay-Tee Khaw</note>
	<note>Hans Wildiers. Robert Winqvist 139 , Xiaohong R. Yang 187 , Drakoulis Yannoukakos 66 , Song Yao 11 , M Pilar Zamora 188 , Wei Zheng 121 , Per Hall 44. Peter Kraft 62,119,189 , Celine Vachon 2 , Susan Slager 2 , Georgia Chenevix-Trench 190, **, Paul D.P Pharoah 55, **, Alvaro A.N Monteiro 4, **, Montserrat Garcı ´a-Closas 191, **, Douglas F. Easton 3, ** &amp; Antonis C. Antoniou 3, **</note>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK. 4 Cancer Epidemiology Program</title>
	</analytic>
	<monogr>
		<title level="j">Mayo Clinic</title>
		<imprint>
			<biblScope unit="issue">2</biblScope>
		</imprint>
		<respStmt>
			<orgName>Department of Laboratory Medicine and Pathology, Mayo Clinic ; H. Lee Moffitt Cancer Center and Research Institute</orgName>
		</respStmt>
	</monogr>
	<note>Department of Health Sciences Research</note>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Department of Health Studies</title>
	</analytic>
	<monogr>
		<title level="j">Human Genetics</title>
		<imprint>
			<biblScope unit="issue">7</biblScope>
			<biblScope unit="page">29</biblScope>
			<date>20133</date>
		</imprint>
		<respStmt>
			<orgName>Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, N-0310 Oslo, Norway. 6 Immunology and Molecular Oncology Unit, Istituto Oncologico Veneto IOV-IRCCS ; The University of Chicago ; The University of Chicago ; Department of Clinical Genetics, Helsinki University Central Hospital</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">15 Division of Clinical Epidemiology and Aging Research</title>
	</analytic>
	<monogr>
		<title level="m">M5G 1X5. 13 Departments of Molecular Genetics and Laboratory Medicine and Pathobiology</title>
				<meeting><address><addrLine>Buffalo, New York; Toronto, Ontario, Canada; University of Toronto, Ontario, Canada; Irvine, California, 92697, USA.</addrLine></address></meeting>
		<imprint>
			<publisher>DKFZ</publisher>
			<date>14263</date>
			<biblScope unit="page">69120</biblScope>
		</imprint>
		<respStmt>
			<orgName>Department of Cancer Prevention and Control, Roswell Park Cancer Institute ; USA. 12 Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital ; University of California Irvine</orgName>
		</respStmt>
	</monogr>
	<note>M5B 1W8. 14 Department of Epidemiology</note>
</biblStruct>

<biblStruct xml:id="b55">
	<monogr>
		<title level="m" type="main">18 Division of Cancer Prevention and Genetics</title>
		<author>
			<persName><forename type="first">Germany</forename><surname>Heidelberg</surname></persName>
		</author>
		<imprint>
			<date>20141</date>
			<biblScope unit="page">17176</biblScope>
			<pubPlace>Houston, Texas 77030, USA; Stockholm, Sweden</pubPlace>
		</imprint>
		<respStmt>
			<orgName>16 University of Texas MD Anderson Cancer Center ; 17 Department of Oncology, Karolinska University Hospital ; Istituto Europeo di Oncologia</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">20 Institute for Quality and Efficiency in Health Care (IQWiG)</title>
		<author>
			<persName><forename type="first">Italy</forename><surname>Milan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Comprehensive Cancer Center Erlangen-EMN</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page">28029</biblScope>
			<date>91054</date>
		</imprint>
		<respStmt>
			<orgName>19 Department of Pathology, Landspitali University Hospital and University of Iceland School of Medicine ; 21 University Breast Center Franconia, Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg</orgName>
		</respStmt>
	</monogr>
	<note>Human Cancer Genetics Program. Spanish National Cancer Centre (CNIO</note>
</biblStruct>

<biblStruct xml:id="b57">
	<monogr>
		<title level="m" type="main">Human Cancer Genetics Program</title>
		<author>
			<persName><forename type="first">Spain</forename><surname>Madrid</surname></persName>
		</author>
		<imprint/>
		<respStmt>
			<orgName>Spanish National Cancer Centre (CNIO</orgName>
		</respStmt>
	</monogr>
	<note>Genotyping Unit (CeGen)</note>
</biblStruct>

<biblStruct xml:id="b58">
	<monogr>
		<author>
			<persName><forename type="first">Spain</forename><surname>Madrid</surname></persName>
		</author>
		<title level="m">24 Biomedical Network on Rare Diseases (CIBERER)</title>
				<imprint>
			<biblScope unit="page">28029</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<monogr>
		<title level="m" type="main">25 NYU Women&apos;s Cancer Program</title>
		<author>
			<persName><forename type="first">Spain</forename><surname>Madrid</surname></persName>
		</author>
		<idno>FI-00029</idno>
		<imprint>
			<pubPlace>New York, New York 10016, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>New York University School of Medicine ; 26 Department of Oncology, University of Helsinki and Helsinki University Central Hospital</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">29 Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology</title>
		<author>
			<persName><forename type="first">Finland</forename><surname>Helsinki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Hannover Medical School</title>
		<imprint>
			<biblScope unit="page">69120</biblScope>
		</imprint>
		<respStmt>
			<orgName>Copenhagen University Hospital ; German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT</orgName>
		</respStmt>
	</monogr>
	<note>31 Division of Preventive Oncology</note>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Salt Lake City Utah 84112, USA. 34 Molecular Oncology Laboratory, Hospital Clinico San Carlos, IdISSC, Madrid 28040, Spain. 35 Section of Genetic Oncology</title>
		<author>
			<persName><forename type="first">Germany</forename><surname>Heidelberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">New South Wales 2145</title>
				<meeting><address><addrLine>I-56126 Pisa, Italy; Heidelberg, Germany; Sydney; Australia</addrLine></address></meeting>
		<imprint>
			<publisher>German Cancer Research Center</publisher>
			<biblScope unit="page">69120</biblScope>
		</imprint>
		<respStmt>
			<orgName>32 Department of Obstetrics and Gynecology, University of Heidelberg, 69120 Heidelberg, Germany. 33 Department of Medicine, Huntsman Cancer Institute, University of Utah School of Medicine ; Department of Laboratory Medicine, University and University Hospital of Pisa ; Westmead Millennium Institute, University of Sydney</orgName>
		</respStmt>
	</monogr>
	<note>37 Australian Breast Cancer Tissue Bank</note>
</biblStruct>

<biblStruct xml:id="b62">
	<monogr>
		<title level="m" type="main">Division of Cancer Epidemiology</title>
		<imprint>
			<publisher>German Cancer Research Center</publisher>
			<biblScope unit="page">69120</biblScope>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">45 Department of Clinical Genetics, Fox Chase Cancer Center</title>
		<author>
			<persName><forename type="first">Germany</forename><surname>Heidelberg</surname></persName>
		</author>
		<idno>USA. 46 INSERM U1052</idno>
	</analytic>
	<monogr>
		<title level="m">Sheffield S10 2HQ, UK. 44 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, SE-17177</title>
				<meeting><address><addrLine>Rockville, Maryland 20850, USA; New York, New York; Stockholm, Sweden; Philadelphia, Pennsylvania; Leiden 2333 ZC, The Netherlands</addrLine></address></meeting>
		<imprint>
			<date>10032. 19111</date>
		</imprint>
		<respStmt>
			<orgName>39 Division of Cancer Epidemiology and Genetics, National Cancer Institute ; Columbia University ; Ghent University, 9000 Ghent, Belgium. 42 Sheffield Cancer Research Centre, Department of Oncology, University of Sheffield ; Department of Neuroscience, University of Sheffield ; CNRS UMR5286, Universite ´Lyon, Centre de Recherche en Cance ´rologie de Lyon, 69373 Lyon, France. 47 Department of Human Genetics and Department of Pathology, Leiden University Medical Center</orgName>
		</respStmt>
	</monogr>
	<note>40 Departments of Pediatrics and Medicine</note>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">60 Comprehensive Cancer Center -EMN, 91054 Erlangen, Germany. 61 Channing Division of Network Medicine, Brigham and Women&apos;s Hospital and Harvard Medical School</title>
		<author>
			<persName><forename type="first">Spain</forename><surname>Barcelona</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medical Biometrics and Epidemiology</title>
		<imprint>
			<biblScope unit="page">69120</biblScope>
			<date>19104. 20246</date>
		</imprint>
		<respStmt>
			<orgName>49 Department of Population Sciences, Beckman Research Institute of City of Hope ; CRO Aviano National Cancer Institute ; Perelman School of Medicine, University of Pennsylvania ; USA. 52 Department of Genetics, University of Pretoria, Pretoria 0007, South Africa. 53 Department of Non-Communicable Disease Epidemiology ; Centre Hospitalier Universitaire de Que ´bec and Laval University ; Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK. 56 Faculty of Medicine, University of Southampton, University Hospital Southampton ; Lund University Hospital, SE-22185 Lund, Sweden. 59 Institute of Human Genetics, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, 91054 Erlangen ; 62 Department of Epidemiology, Harvard School of Public Health ; University Clinic Hamburg-Eppendorf</orgName>
		</respStmt>
	</monogr>
	<note>Genetics and Pathology. 64 Division of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ</note>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">North Carolina 27599-7400, USA. 71 UCLA Schools of Medicine and Public Health, Division of Cancer Prevention and Control Research</title>
		<author>
			<persName><forename type="first">Germany</forename><surname>Heidelberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Jonsson Comprehensive Cancer Center</title>
		<imprint>
			<biblScope unit="volume">90048</biblScope>
			<biblScope unit="issue">65</biblScope>
			<biblScope unit="page">15310</biblScope>
			<date>19104</date>
			<publisher>American Cancer Society</publisher>
		</imprint>
		<respStmt>
			<orgName>Center for Primary Health Care Research, Lund University, SE-221 00 Malmo ¨, Sweden. 66 Molecular Diagnostics Laboratory, INRASTES, National Centre for Scientific Research &apos;Demokritos&apos;, Aghia Paraskevi Attikis ; McGill University ; 68 University of ; Israel. 70 Department of Epidemiology, University of, Chapel Hill ; Dana Farber Cancer Institute ; 74 Department of Biomedical Sciences ; USA. 75 Department of Clinical Genetics, Rigshospitalet, Copenhagen University Hospital</orgName>
		</respStmt>
	</monogr>
	<note type="report_type">Tel-Hashomer 52621</note>
	<note>Cedars Sinai Medical Center</note>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Cancer Council Victoria</title>
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiology Centre</title>
		<imprint>
			<biblScope unit="volume">3010</biblScope>
		</imprint>
		<respStmt>
			<orgName>Australia. 77 Department of Pathology and Laboratory Medicine, University of Kansas Medical Center ; 78 Department of Medicine, McGill University</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">H4A 3J1. 80 Department of Dermatology</title>
	</analytic>
	<monogr>
		<title level="j">Human Cancer Genetics Program</title>
		<imprint>
			<biblScope unit="page">28029</biblScope>
		</imprint>
		<respStmt>
			<orgName>Division of Clinical Epidemiology, McGill University Health Centre, Royal Victoria Hospital ; Huntsman Cancer Institute, University of Utah School of Medicine ; Spanish National Cancer Research Centre (CNIO</orgName>
		</respStmt>
	</monogr>
	<note>81 Human Genotyping-CEGEN Unit</note>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">84 Inserm (National Institute of Health and Medical Research), CESP (Center for Research in Epidemiology and Population Health), U1018, Environmental Epidemiology of Cancer</title>
		<author>
			<persName><forename type="first">Spain</forename><surname>Madrid</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Molecular Genetics of Breast Cancer</title>
		<imprint>
			<biblScope unit="volume">87</biblScope>
			<biblScope unit="page">69120</biblScope>
			<date>20850-9772</date>
			<publisher>DKFZ</publisher>
		</imprint>
		<respStmt>
			<orgName>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health ; USA. 83 Department of Genetics and Pathology, Pomeranian Medical University ; 85 Department of of Epidemiology and Biostatistics ; Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center</orgName>
		</respStmt>
	</monogr>
	<note>86 Department of Preventive Medicine</note>
</biblStruct>

<biblStruct xml:id="b69">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Germany</forename><surname>Heidelberg</surname></persName>
		</author>
		<idno>DK-2100</idno>
		<imprint>
			<biblScope unit="volume">88</biblScope>
		</imprint>
		<respStmt>
			<orgName>Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<monogr>
		<title level="m" type="main">90 Helsinki University Central Hospital, FI-00029 Helsinki, Finland. 91 Clinical Cancer Genetics, for the City of Hope Clinical Cancer Genetics Community Research Network</title>
		<author>
			<persName><forename type="first">Denmark</forename><surname>Copenhagen</surname></persName>
		</author>
		<imprint>
			<pubPlace>Brisbane, Queensland 4029, Australia; Duarte, California 91010, USA; Netherlands Cancer Institute, Amsterdam 1000 BE, The Netherlands</pubPlace>
		</imprint>
		<respStmt>
			<orgName>89 Department of Genetics, QIMR Berghofer Medical Research Institute ; 93 Department of Medical Oncology</orgName>
		</respStmt>
	</monogr>
	<note>92 Family Cancer Clinic</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">98 Lombardi Comprehensive Cancer Center</title>
		<author>
			<persName><forename type="first">Erasmus</forename><surname>Mc Cancer Institute</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Australia. 96 Program in Molecular and Genetic Epidemiology</title>
		<imprint>
			<biblScope unit="volume">3010</biblScope>
			<biblScope unit="page">8200</biblScope>
			<date>197758</date>
			<publisher>Peter MacCallum Cancer Centre</publisher>
		</imprint>
		<respStmt>
			<orgName>Rotterdam 3008 AE, The Netherlands. 94 Department of Medical Oncology, Family Cancer Clinic, Erasmus University Medical Center, Rotterdam 3008 AE, The Netherlands. 95 Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne ; N. Petrov Institute of Oncology ; Georgetown University ; Australia. 100 Department of Oncology, The University of Melbourne ; Australia. 101 State Research Institute Centre for Innovative Medicine, LT-08661 Vilnius, Lithuania. 102 Department of Clinical Genetics, Aarhus University Hospital</orgName>
		</respStmt>
	</monogr>
	<note>99 Familial Cancer Centre</note>
</biblStruct>

<biblStruct xml:id="b72">
	<monogr>
		<title level="m" type="main">103 Department of Epidemiology, Cancer Prevention Institute of California</title>
		<author>
			<persName><forename type="first">N</forename><surname>Aarhus</surname></persName>
		</author>
		<author>
			<persName><surname>Denmark</surname></persName>
		</author>
		<imprint>
			<pubPlace>Fremont, California 94538, USA; Sutton SM2 5NG, UK</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Institute of Cancer Research</orgName>
		</respStmt>
	</monogr>
	<note>104 Division of Genetics and Epidemiology</note>
</biblStruct>

<biblStruct xml:id="b73">
	<monogr>
		<title level="m" type="main">Women&apos;s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center</title>
		<imprint>
			<pubPlace>Los Angeles, California, 90048, USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">110 School of Medicine, Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Eastern Finland, FI-70211 Kuopio, Finland. 111 The Hong Kong Hereditary Breast Cancer Family Registry</title>
	</analytic>
	<monogr>
		<title level="j">Genetic Epidemiology and Statistical Genetics</title>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="page">8908</biblScope>
			<date>138672</date>
		</imprint>
		<respStmt>
			<orgName>Department of Obstetrics and Gynecology, University of Helsinki and Helsinki University Central Hospital, FI-00029 Helsinki, Finland. 107 Department of Public Health and Primary Care, University of Cambridge, Strangeways Research Laboratory, Cambridge CB1 8RN, UK. 108 Prosserman Centre for Health Research, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital ; 109 Department of Internal Medicine, Evangelische Kliniken Bonn gGmbH, Johanniter Krankenhaus ; Hong Kong Sanatorium and Hospital, Hong Kong. 112 Department of Surgery, The University of Hong Kong ; 115 Department of Preventive Medicine, University of Southern California ; University of Cancer Center ; 117 Department of Molecular Medicine and Surgery</orgName>
		</respStmt>
	</monogr>
	<note>Harvard School of Public Health. 120 Human Genetics Division, Genome Institute of Singapore</note>
</biblStruct>

<biblStruct xml:id="b75">
	<monogr>
		<title level="m" type="main">USA. 122 Division of Public Health Sciences</title>
		<imprint>
			<biblScope unit="volume">37203</biblScope>
			<pubPlace>Nashville, Tennessee; Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA; Seattle, Washington 98195, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine ; Department of Epidemiology, School of Public Health and Community Medicine, University of Washington</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title/>
	</analytic>
	<monogr>
		<title level="j">Fondazione IRCCS Istituto Nazionale Tumori</title>
		<imprint>
			<biblScope unit="page">20133</biblScope>
			<publisher>INT</publisher>
		</imprint>
		<respStmt>
			<orgName>Unit of Medical Genetics, Department of Preventive and Predictive Medicine</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">Italy</forename><surname>Milan</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<monogr>
		<title level="m" type="main">126 NRG Oncology Statistics and Data Management Center</title>
		<imprint>
			<biblScope unit="volume">44106</biblScope>
			<biblScope unit="page" from="1W" to="8" />
			<pubPlace>Munich, Germany; Roswell Park Cancer Institute, Buffalo, New York 14263, USA; Cleveland, Ohio; Toronto, Ontario, Canada</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Department of Gynaecology and Obstetrics, Technical University of Munich ; Case Western Reserve University Medical School ; USA. 128 Laboratory Medicine Program, University Health Network</orgName>
		</respStmt>
	</monogr>
	<note>127 Department of Genomics and Genome Sciences</note>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">133 Center for Clinical Cancer Genetics and Global Health</title>
	</analytic>
	<monogr>
		<title level="m">M5B 1W8. 130 Invitae Corporation</title>
				<meeting><address><addrLine>Toronto, Ontario, Canada; San Francisco, California; New York, New York 10065, USA; Budapest, Hungary; Chicago, Illinois 60637, USA; Seoul, Republic of Korea; Utrecht 3508 GA, The Netherlands; Imperial College London</addrLine></address></meeting>
		<imprint>
			<publisher>School of Public Health</publisher>
			<date>20133</date>
			<biblScope unit="volume">136</biblScope>
			<biblScope unit="page" from="110" to="799" />
		</imprint>
		<respStmt>
			<orgName>Department of Laboratory Medicine and Pathobiology, University of Toronto ; USA. 131 Department of Medicine, Memorial Sloan-Kettering Cancer Center ; National Institute of Oncology ; University of Chicago Medical Center ; 134 Department of Preventive Medicine and Biomedical Science, Seoul National University College of Medicine and Cancer Research Institute, Seoul National University ; MRC-PHE Centre for Environment and Health, Department of Epidemiology and Biostatistics</orgName>
		</respStmt>
	</monogr>
	<note>University Medical Center. London SW7 2AZ, UK. 137 IFOM, Fondazione Istituto FIRC di Oncologia Molecolare</note>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">Hospital, FI-90220 Oulu, Finland. 140 Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine</title>
		<author>
			<persName><forename type="first">Italy</forename><surname>Milan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Fondazione IRCCS Istituto Nazionale Tumori</title>
		<imprint>
			<biblScope unit="volume">43210</biblScope>
			<biblScope unit="page">20133</biblScope>
			<publisher>INT</publisher>
		</imprint>
		<respStmt>
			<orgName>138 Divison of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University ; Department of Clinical Chemistry and Biocenter Oulu, University of Oulu, NordLab Oulu/ Oulu University</orgName>
		</respStmt>
	</monogr>
	<note>USA. 139 Laboratory of Cancer Genetics and Tumor Biology</note>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">143 Department of Obstetrics and Gynecology, Comprehensive Cancer Center</title>
		<author>
			<persName><forename type="first">Italy</forename><surname>Milan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Carmel Medical Center and B. Rappaport Faculty of Medicine</title>
		<imprint>
			<biblScope unit="volume">34362</biblScope>
			<biblScope unit="page">69008</biblScope>
		</imprint>
		<respStmt>
			<orgName>Institute of Cancer Research, Sutton SM2 5NG, UK. 142 Department of Clinical Genetics, Karolinska University Hospital ; Medical University of Vienna, A 1090 Vienna, Austria. 144 Clalit National Israeli Cancer Control Center and Department of Community Medicine and Epidemiology ; Israel. 145 Department of Pathology, Johns Hopkins University School of Medicine</orgName>
		</respStmt>
	</monogr>
	<note>Haifa. 146 International Agency for Research on Cancer</note>
</biblStruct>

<biblStruct xml:id="b82">
	<monogr>
		<title level="m" type="main">Amsterdam 1006 BE, The Netherlands. 148 Escuela Andaluza de Salud Pu ´blica. Instituto de Investigacio ´n Biosanitaria ibs.GRANADA, Hospitales Universitarios de Granada/Universidad de Granada, 18014 Granada, Spain. 149 CIBER de Epidemiologı ´a y Salud Pu ´blica (CIBERESP), Spain. 150 Department of Environmental Health Sciences</title>
		<imprint>
			<pubPlace>New York, New York, 10032, USA</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital ; Columbia University</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Division of Cancer Studies, King&apos;s College London, Guy&apos;s Hospital, London SE1 9RT, UK. 152 Center for Hereditary Breast and Ovarian Cancer</title>
	</analytic>
	<monogr>
		<title level="m">Medical Faculty</title>
				<meeting><address><addrLine>Cologne, Germany; Cologne, Germany</addrLine></address></meeting>
		<imprint>
			<biblScope unit="volume">50931</biblScope>
			<biblScope unit="page">50931</biblScope>
		</imprint>
		<respStmt>
			<orgName>University Hospital Cologne ; University Hospital Cologne ; Center for Molecular Medicine Cologne (CMMC), University of Cologne</orgName>
		</respStmt>
	</monogr>
	<note>Research Oncology</note>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">158 Unite ´Mixte de Ge ´ne ´tique Constitutionnelle des Cancers Fre ´quents, Hospices Civils de Lyon-Centre Le ´on Be ´rard</title>
	</analytic>
	<monogr>
		<title level="m">New South Wales 2305</title>
				<meeting><address><addrLine>Newcastle; Australia; Kansas City, Kansas 66205, USA; Quebec City, Quebec, Canada G1V 4G2; Lyon, France; Melbourne, Victoria, Australia</addrLine></address></meeting>
		<imprint>
			<publisher>John Hunter Hospital</publisher>
			<biblScope unit="page">69373</biblScope>
		</imprint>
		<respStmt>
			<orgName>Division of Genetics, Hunter Area Pathology Service ; 156 Department of Hematology and Oncology, University of Kansas Medical Center ; Centre Hospitalier Universitaire de Que ´bec Research Center, Laval University ; 159 Department of Pathology, The University of Melbourne</orgName>
		</respStmt>
	</monogr>
	<note>160 Hannover Medical School</note>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">167 Cancer Research Initiatives Foundation, Sime Darby Medical Centre, Subang Jaya 47500, Malaysia. 168 University Malaya Cancer Research Institute, Faculty of Medicine</title>
		<author>
			<persName><forename type="first">Germany</forename><surname>Hannover</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">Portugal. 166 Biomedical Sciences Institute (ICBAS)</title>
				<meeting><address><addrLine>Paris, France; Bethesda, Maryland; Porto; Porto University; Porto, Portugal; New York, New York, 10032, USA</addrLine></address></meeting>
		<imprint>
			<date type="published" when="2152">20892-2152</date>
			<biblScope unit="page">5000</biblScope>
		</imprint>
		<respStmt>
			<orgName>Department of Clinical and Experimental Medicine, Linko ¨ping University, SE-58185 Linko ¨ping, Sweden. 162 Institut Curie, Department of Tumour Biology ; USA. 165 Department of Genetics, Portuguese Oncology Institute ; University Malaya Medical Centre, University Malaya, Kuala Lumpur 50603, Malaysia. 169 Department of Epidemiology, Mailman School of Public Health, Columbia University ; 170 Department of Clinical Genetics, Odense University Hospital</orgName>
		</respStmt>
	</monogr>
	<note>163 Universite ´Paris Descartes, Sorbonne Paris Cite ´, 75248 Paris, France. 164 National Human Genome Research Institute</note>
</biblStruct>

<biblStruct xml:id="b86">
	<monogr>
		<title/>
		<author>
			<persName><forename type="first">C</forename><surname>Odense</surname></persName>
		</author>
		<author>
			<persName><surname>Denmark</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">LV-1067 Riga, Latvia. 172 Department of Molecular Virology</title>
		<author>
			<persName><forename type="first">Biomedical</forename><surname>Latvian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Study</forename><surname>Research</surname></persName>
		</author>
		<author>
			<persName><surname>Centre</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Immunology and Medical Genetics</title>
		<imprint/>
		<respStmt>
			<orgName>The Ohio State University ; 173 Department of Surgical Oncology, Leiden University Medical Center</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<monogr>
		<title level="m" type="main">Oxford OX3 7BN, UK. 175 Genetic Counseling Unit, Hereditary Cancer Program, IDIBELL-Catalan Institute of Oncology</title>
		<imprint>
			<biblScope unit="page">8908</biblScope>
			<pubPlace>Barcelona, Spain</pubPlace>
		</imprint>
		<respStmt>
			<orgName>Wellcome Trust Centre for Human Genetics and Oxford Biomedical Research Centre, University of Oxford</orgName>
		</respStmt>
	</monogr>
	<note>176 Cancer Registry and Histopathology Unit</note>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">177 Department of Medical Oncology</title>
		<author>
			<persName><surname>Arezzo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Beth Israel Deaconess Medical Center</title>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">181 Cancer Genomics Research Laboratory, Division of Cancer Epidemiology and Genetics, National Cancer Institute</title>
	</analytic>
	<monogr>
		<title level="j">Charite Berlin</title>
		<imprint>
			<biblScope unit="volume">89075</biblScope>
			<date type="published" when="2016">13353. 2016</date>
		</imprint>
		<respStmt>
			<orgName>Cancer Registry of Norway, Institute of Population-Based Cancer Research, N-0304 Oslo, Norway. 179 Department of Pathology, Family Cancer Clinic, Erasmus University Medical Center ; 182 University Hospital Ulm ; University of Tromsø-The Arctic University of Norway, 9037 Tromsø, Norway. 184 Genetic Epidemiology Group, Folkha ¨lsan Research Center</orgName>
		</respStmt>
	</monogr>
	<note>183 Department of Community Medicine, Faculty of Health Sciences</note>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
